CONNECT WITH US
Apple

Apple

Apple's $634 Million Apple Watch Patent Bill Just Got Even Bigger

MacRumors - Apple logo

Published on

Add as a preferred source on Google
Apple's $634 Million Apple Watch Patent Bill Just Got Even Bigger

Apple's $634 million patent loss to medical technology company Masimo has just gotten even bigger, after a federal judge ordered Apple to pay an additional $184 million in interest on what it owes (via Bloomberg Law ). The ruling takes Apple's bill to around $818 million, but that doesn't include any post-judgment interest continuing to accrue until the judgment is paid. S. " Put another way, Masimo is being compensated for as long as it was deprived of royalty payments that it theoretically would have received during the infringement period. It didn't all go Masimo's way, though. Selna also declined Masimo's request to calculate it at a 7 percent rate, which would have put Apple's interest bill at $243 million. Instead, the court used Masimo's own borrowing rate, compounding annually from when the infringement began. S. import ban on certain Apple Watch models and resulted in Apple disabling blood oxygen functionality on affected newly sold models. Apple in 2025 introduced a redesigned version of the feature. The dispute here is concerned with a Masimo pulse-oximetry patent. In November 2025, a jury found that Apple Watch features including heart-rate notifications infringed Masimo's patent and awarded the company $634 million. Apple subsequently tried to overturn or reduce the award, but Selna upheld the verdict in July. The patent in question expired in June 2022, so the ruling related to historical Apple Watch sales and has no effect on the heart-rate features in current Apple Watch models.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.